Medical/Pharmaceuticals
Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to la...
2025-06-13 00:01
2053
Turning Partnerships into Global Healthcare Solutions with VARON Oxygen Solutions
NEW YORK, June 12, 2025 /PRNewswire/ -- In hospitals, senior living centers,
and clinics around the globe, lives are being improved every day by a quiet but
powerful force in respiratory care: VARON Oxygen Solutions.
2025-06-12 20:50
1407
Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases
CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), today announced a license agreement with Visterra, Inc. to advance Visterra's next-generation biotherapeutic pipeline for immune-mediated ...
2025-06-12 20:03
1772
Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
* Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS) rate of 74.2% * DZD8586 exhibited significant antitumor activity in heavily pretreated chronic l...
2025-06-12 18:13
1694
Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025
BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking placeJune 16-19 in Boston Convention & Exhibition Cen...
2025-06-12 15:39
1756
Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand
HONG KONG and SHANGHAI, June 11, 2025 /PRNewswire/ -- The Ping An Good Doctor Brand Revamp & Ping An Healthcare Services Brand Launch Conference was held in Shanghai. Ping An Healthcare and Technology Company Limited ("the Company", Stock Code: 1833.HK) officially revamped its brand to "Ping An Go...
2025-06-11 19:32
4968
Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025
TAIPEI, June 11, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking placeJune 16–19 in Boston, MA. The c...
2025-06-11 15:58
1847
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- ...
2025-06-11 12:00
2169
Insilico Medicine Launches Nach01 Foundation Model on AWS Marketplace to Help Accelerate Generative Chemistry Innovation
CAMBRIDGE, Mass., June 10, 2025 /PRNewswire/ -- Insilico Medicine
2025-06-10 21:00
2019
ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
SUZHOU, China, June 10, 2025 /PRNewswire/ -- ImmVira, a global leading clinical-stage biotechnology company focused on the development of next-generation novel oncolytic immunotherapy for treatment of cancer, announced that the first patient diagnosed with NMIBC has been dosed in a multi-regiona...
2025-06-10 20:00
2203
Sanyou Biopharmaceuticals and Medicovestor, Inc. Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
SHANGHAI and NEW YORK, June 10, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leadingShanghai-based high-tech biopharmaceutical company specializing in biologics R&D today announced the signing of a strategic cooperation agreement with Medicovestor, Inc., aNew York-based biotechnology company...
2025-06-10 18:00
1763
Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy
* LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals inthe United States and Europe, who progress rapidly to end-stage heart failure. * NVC-001 demonstrated significant benefits, including survival and cardiac ...
2025-06-10 16:49
1533
Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025
* Caliway to deliver a corporate presentation on June 17 at the BIO International Convention 2025, the world's largest biotech industry event. * For the first time at an international conference, Caliway will share preclinical results on CBL-514's potential new indication: combined withGLP-1 ...
2025-06-10 16:15
1486
Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT
SHANGHAI, June 10, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for pimicotinib, a highly selective, small-molecule CSF-1R inhibitor, as a Class 1 innovati...
2025-06-10 12:02
1641
VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.
HONG KONG and WENZHOU, China, June 9, 2025 /PRNewswire/ -- VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced today that it received written preliminary comments for the Type C meeting to be held in e...
2025-06-10 00:00
1927
Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME)
* EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R * Improvements in Visual Acuity and Retinal Edema Observed at All Dose Levels * No Safety Issues Observed Following a Single Intravitreal (IVT) Injection * Multiple Ascending Dose Study Planned for Q3 2025 in DME MOUNTAIN VIEW, Calif., J...
2025-06-10 00:00
1998
World's First HLA-G Targeted Exosome Therapy for Cancer Enters U.S. Clinical Trials
FDA Greenlights SOB100 for Phase I; Breakthrough Study Published in Nature Communications TAICHUNG, June 9, 2025 /PRNewswire/ -- A research team led by Dr. Der-Yang Cho, Superintendent of China Medical University Hospital (Taiwan), in collaboration with Shine-On Biomedical Co., has developed the...
2025-06-09 20:03
1633
Planet Green Advances AI-Powered Early Mental Health Intervention for Youth in Post-Pandemic Canada
NEW YORK, June 9, 2025 /PRNewswire/ -- Planet Green Holdings Corp. ("Planet Green", the "Company") (NYSE American: PLAG) announced that its subsidiary Fast Approach Inc., ("Fast Approach"), a leader in applied AI technology, today announced a groundbreaking initiative in mental healthcare: the de...
2025-06-09 20:00
3368
Neowise Biotechnology and BeOne Medicines Enter Licensing Agreement to Advance Development of Next-Generation Cell Therapies
SUZHOU, China, June 9, 2025 /PRNewswire/ -- Neowise Biotechnology ("Neowise"), a pioneering company focused on the development of TCR-T cell therapies for solid tumors, announced today that it has entered into a non-exclusive licensing agreement with BeOne Medicines Ltd. ("BeOne"). Under the term...
2025-06-09 20:00
1663
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, andTaiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ ...
2025-06-09 19:00
1831
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Synvo AI and Sobat Bisnis Group (SBG) Forge Strategic Partnership to Bring Secure, Context-Aware Enterprise AI to Indonesia and Southeast Asia
[Picked up by 290 media titles]
2025-12-16 08:00
Colebrook Bosson Saunders Chooses India for First Executive Dialogue Exploring Future of Workspaces and Technology
[Picked up by 287 media titles]
2025-12-16 14:26
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
